Sales revenue growth of 17% by CSL Bioplasma to $209 million this year has been underpinned by the impact of merging the ZLB Behring commercial activities in Asia (with the exception of Japan) into our business, and also the increasing demand for INTRAGAM® P (intravenous immunoglobulin) in markets where we provide contract fractionation services.

In January 2005, we were proud to announce the signing of a new Plasma Products Agreement (PPA) with the National Blood Authority (NBA) which now acts on behalf of all Australian State and Federal governments. Under the new five-year agreement, and in collaboration with the Australian Red Cross Blood Service, we will provide the life saving plasma-derived therapeutics that meet the rigorous Australian requirements for safety, security and reliability of access by the medical community. Through close cooperation with the NBA, we have achieved a smooth transition to the new arrangements included in the PPA.

The successful integration of ZLB Behring's regional commercial operations with CSL Bioplasma has created a strong platform for our business growth in the Asia Pacific region by adding a diverse portfolio to our existing plasma-derived therapeutic products.

By taking advantage of the complementary strengths of CSL Bioplasma and ZLB Behring, we can now provide an extensive range of life-saving therapeutic products and services to governments, medical professionals and patients. We can offer the broadest range of products in our industry, customised contract fractionation for blood services throughout our region, and enhanced client support through our direct presence in key markets.

We have executed a five-year agreement with Bayer HealthCare granting CSL the exclusive Australian distribution rights for KOGENATE® FS (recombinant coagulation Factor VIII octacog alpha). KOGENATE® FS complements our comprehensive portfolio of trusted coagulation therapies used in the treatment of bleeding disorders such as Haemophilia A and Von Willebrand disease. This new collaboration with Bayer HealthCare brings together two organisations with complementary expertise and strengths that will benefit Australia’s haemophilia community.

In July 2004, Australia’s Federal Government announced a change in policy regarding the provision of in-vitro diagnostic reagents used in assessing the compatibility of donor-recipient blood. CSL had provided these reagents to pathology laboratories throughout Australia since 1993 by agreement with the Federal Government. As part of the NBA's new national procurement arrangements introduced on 1 July 2005, we have been accredited as a provider of in-vitro diagnostic reagents. The breadth and quality of our products has helped ensure we remain a major provider of diagnostics with a pivotal role in transfusion medicine in Australia.

Back | Next